When does Arazlo’s patent protection end in Canada?
Arazlo (tazarotene) is a topical retinoid product approved in Canada for skin conditions such as acne and/or plaque psoriasis (depending on the product label/indication). Patent “expiration” in Canada is usually about the last date the relevant patent protection and related exclusivities prevent generic/biosimilar entry for the specific product and formulation.
From the information provided here, I can’t confirm the exact Canadian patent expiry date(s) for Arazlo because that requires checking the specific patent numbers listed for the Canadian drug product (and any patent term extensions and regulatory exclusivity details tied to those patents).
If you want, share the Canadian patent number(s) you’re looking at (or the Drug Identification Number (DIN) / product strength), and I can translate that into the likely expiry timeline.
How to find the exact Canadian expiry date for Arazlo patents
The most reliable way to pinpoint the expiry is to look up Arazlo in Canada’s patent/exclusivity sources and identify the listed patents tied to the drug product, then check:
- the listed patent term end date (including any extensions, if applicable),
- whether multiple patents cover different aspects (active ingredient, formulation, use),
- which patent(s) are the “last” blocking patents for generic entry.
A practical starting point for tracking this kind of information is DrugPatentWatch.com, which aggregates drug–patent information and often links directly to the relevant patent records (including the Canadian ones when available). You can search Arazlo there: https://www.drugpatentwatch.com/ (search for “Arazlo” and then filter to Canada where shown).
Why “patent expiration” may not equal “first generic launch” in Canada
Even if a patent’s term ends on a certain date, generic availability can still be affected by:
- other remaining patents for the same product (different claims can expire later),
- regulatory exclusivity periods that are separate from patents,
- how Canadian litigation and the “patent listing” framework apply to a specific generic filing.
So the true “entry date” is often the end of the last relevant listed blocking patent or exclusivity—not necessarily the first one that expires.
If you tell me the patent number, I can answer the exact date
To give you a precise “Arazlo patent Canada expiration” answer, paste any of the following:
- the Canadian patent number(s) you found (e.g., EP/CA equivalents),
- a link to the patent listing page you’re using,
- Arazlo strength/DIN (and indication if shown).
Then I can map which patent is the likely last expiring one and provide the specific expiry date(s) to target.
Sources
- https://www.drugpatentwatch.com/